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Introduction
The common causes of maternal thrombocytopenia in
pregnancy are gestational thrombocytopenia, pre-
eclampsia, immunologic etiologies (including idiopath-
ic thrombocytopenia purpura [ITP], systemic lupus
erythematosus [SLE], heparin-induced thrombocyto-
penia [HIT], and alloimmune thrombocytopenia),
viral infection, B12 or folic acid shortage and hyper-
splenism.1,2 The presence of antiplatelet antibodies may
induce platelet aggregation and precipitate destruc-
tion of antibody-coated platelets by reticuloendothelial
uptake. Intravenous immunoglobulin (IVIG)-induced
immunomodulation derived from management of ITP
may apply to other immune-induced thrombocytope-
nia.3–5 Herein, the experience of using IVIG in the
management of severe maternal thrombocytopenia in
association with heparin administration, HELLP
(hemolysis, elevated liver function, low platelets) syn-
drome, and SLE, is presented. Both the mechanisms
and side effects of IVIG are also briefly reviewed.
Case Reports
Case 1
A 24-year-old woman with pulmonary hypertension
and suspected postpartum pulmonary embolism on
the third postpartum day was treated with unfraction-
ated heparin, urokinase, and extracorporeal mem-
brane oxygenation (ECMO) therapy. After 6 days of
heparin administration, severe thrombocytopenia
(18,000/mm3) was noted, which did not respond 
to repeated platelet transfusion. Heparin infusion was
stopped due to HIT. Unfortunately, deteriorating pul-
monary hypertension with massive bilateral pulmonary
hemorrhage subsequently occurred. Platelet transfu-
sion and IVIG (GAMMAR-P I.V., Aventis Behring,
USA) were administered (15 g/d for 3 days). Four
days after initiation of IVIG therapy, the platelet count
increased and was maintained above 77,000/mm3 with-
out further platelet transfusion. The ECMO therapy
was continued for 33 days to successfully rescue the
patient’s life.
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Case 2
A 35-year-old woman with HELLP syndrome and
acute postpartum uterine bleeding was treated with
platelet transfusion, prostaglandin E1, and IVIG (15 g,
single dose; GAMMAR-PI.V., Aventis Behring) because
of worsening hemolytic renal failure and thrombocy-
topenia (23,000/mm3). Platelet counts increased to
110,000/mm3 within 6 hours and were maintained
above 65,000/mm3 without further transfusion. Uter-
ine bleeding was under control and hemoglobinuria
improved over 2 days despite persistent severe oliguria.
Unfortunately, pulmonary edema ensued, then hemo-
dialysis was initiated. The patient’s condition became
stable gradually. On postpartum day 14, renal biopsy
revealed interstitial nephritis with infiltrating eosinophils
and lymphocytes as well as membranous glomerulone-
phritis (Figure 1). Two weeks later at follow-up, renal
function had normalized.
Case 3
A 30-year-old woman with SLE was noted to have
rupture of membranes at 37 weeks’ gestation. Her pre-
natal care was notable for unstable lupus activity with
fluctuation of platelet level (with nadir of 4,000/mm3),
which was managed with immunotherapy (prednis-
olone and methylprednisolone) and platelet transfu-
sions. At admission, she had no lupus nephritis, but
laboratory data were significant for severe thrombocy-
topenia (8000/mm3). Hydrocortisone (100 mg q6hr),
IVIG (40 g, single dose; Gamimune, Bayer, USA)
and platelet transfusion (18 units) were administered.
Twenty hours later, the platelet count increased to
72,000/mm3 and cesarean section was performed due
to breech presentation. Her postpartum course was
uneventful. The platelet level was maintained above
70,000/mm3 for 2 weeks without further platelet
transfusion.
Discussion
The possible mechanisms of IVIG in clinical use may
involve interaction of pathologic antibodies with anti-
idiotype antibodies in IVIG, competitive inhibition of
autoantibody adsorption to the platelets, prevention
of reticuloendothelial uptake of autoantibody-coated
platelets through Fc-receptor (FcR) blockade by dimer-
ized aggregates in IVIG, acceleration of catabolism of
pathologic antibody by competitive binding to the
molecule FcRn, or the presence of anticytokine anti-
bodies and neutralizing antibodies against toxin and
pathologic antigen.4 The side effects of IVIG include
anaphylaxis, headache, aseptic meningitis, thrombosis
(due to high viscosity), renal toxicity, hemolysis (due to
anti-D,A,B dependent on manufacturers), and neutro-
penia with dyspnea (due to antineutrophil Ab). Most
cases of IVIG-associated acute renal failure (ARF) are
reversible, with approximately 2-week duration and
serum creatinine peaking at day 5. ARF may occur with
sucrose-stabilized IVIG, rarely with maltose-stabilized
IVIG, but not with d-sorbitol-stabilized IVIG, possi-
bly due in part to osmotic damage to renal tubular
cells.4,5–7 In addition, IVIG may induce reversible inter-
stitial nephritis8 and membranous glomerulonephritis.
Other risk factors for IVIG-associated ARF include old
age, diabetes mellitus, nephrotoxic agents, hypov-
olemia, and high dose of IVIG.
HIT type I is a non-immune, mild (rarely
<100,000/mm3) and transient thrombocytopenia that
develops early (within 2 days of starting heparin) and
resolves quickly once the heparin is stopped.9 HIT
type II is a common (incidence of 1–5%) and poten-
tial life-threatening condition which usually occurs
5–7 days after initial use of unfractionated heparin.
Immunoglobulin G antibodies bound to the heparin-
platelet factor 4 complex cause platelet activation via
the FcR. Activated platelets release platelet factor 4,
thus perpetuating the cycle of heparin-induced
platelet activation, which results in thrombocytope-
nia.9 Additionally, platelet factor 4 that is bound to
endothelial cell surface heparin sulfate may bind to
HIT antibodies, possibly precipitating intravascular
coagulation and thrombosis.9 IVIG may have a bene-
ficial effect on HIT.10,11 In our case, IVIG appeared
effective in facilitating recovery from HIT, possibly due
to inhibition of HIT antibody through anti-idiotype
antibody, acceleration of HIT antibody catabolism by
competitive binding to FcRn on endothelial cells,5 and
Figure 1. Electron microscope image shows early membranous
glomerulonephritis with scattered subepithelial electron dense
deposits (arrows). B = basement membrane; EP = epithelial cyto-
plasm; CAP = capillary lumen.
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competitive blockade of FcRII on platelets.10,11
Further studies are needed to elucidate the potential
role of IVIG in management of HIT. Also, using
IVIG to inhibit platelet activation prior to clearance
of residual heparin helps stabilize pulmonary hemor-
rhage, thus providing an opportunity to support the
patient’s life with intensive care and ECMO ther-
apy.12 Furthermore, through inhibition of HIT anti-
body, IVIG may prevent subsequent fatal thrombosis.
As to management of severe HELLP syndrome
associated with postpartum uterine hemorrhage, the
major aim is to interrupt cascading thrombocytopenia
in order to eliminate further hemorrhage and reduce
the requirement for repeated blood transfusions which
may exacerbate pulmonary edema in the situation of
hemolysis-induced renal failure. In association with
platelets transfusion, IVIG seemed to be able to keep
platelets count at a safe level in the acute stage of
HELLP syndrome. In addition, high-dose steroid
may improve laboratory data in HELLP syndrome.
Although its exact mechanism remains unknown, IVIG
may exert effects through modulation of Fc receptor
expression on leukocytes and endothelial cells, and
modulation of cytokine release.5 Cytokines released
by activating leukocytes and lipid peroxide are poten-
tial mediators of endothelial dysfunction.13
IVIG has been used to successfully treat active SLE
with various manifestations, including thrombocy-
topenia.2,5,14 The possible mechanisms are Fc recep-
tor blockage in reticuloendothelial cells, anti-idiotype
antibody, downregulation of autoantibody produc-
tion, neutralization of autoantibody, inhibition of
complement-mediated damage, and modulation of
production of cytokine.5 In addition to platelet trans-
fusion and steroid administration, using IVIG may
expedite the recovery of thrombocytopenia in SLE
during delivery. Besides, IVIG may exert effect on
maintaining a safe platelet level for several weeks with-
out further platelet transfusion on account of its long
half-life. Other advantages include lessening peripar-
tum bleeding, shortening hospital stay, decreasing risk
of infection from using steroid, and allowing more time
for steroid to stabilize the lupus activity.
In conclusion, IVIG may be beneficial in the manage-
ment of severe peripartum maternal thrombocytopenia
in association with HIT, HELLP syndrome, and SLE,
and it should be a last option.
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